User Surveillance in Ulcerative Colitis

Ferring Pharmaceuticals500 enrolled

Overview

The aim of the non-interventional study is to document the daily doses in acute and remission therapy, the frequence of doses (1, 2, 3 or 4 times daily), when rectal dosage forms are added and, when and how long steroids are given.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Ulcerative Colitis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * therapeutic need according to SPC * written informed consent Exclusion Criteria: * contraindications according to SPC

Locations (105)

Outcomes

Primary Outcomes

Prescription habits measured by daily dose of Mesalazine

Time frame: 0 - 8 weeks

Secondary Outcomes

Compliance measured by questionnaire for drug intake

Time frame: 0 - 8 weeks

Quality of Life measured by EuroQol Questionnaire

Time frame: 0 - 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Investigational , Karlsplatz 18

Aalen, Germany

Investigational Site, Goethestraße 5

Ansbach, Germany

Investigational Site, Elisenstraße 32

Aschaffenburg, Germany

Investigational Site, Haingasse 22

Bad Homburg, Germany

Investigational Site, Blankenburger Chaussee 86

Berlin, Germany

Investigational Site, Etkar-André-Straße 8

Berlin, Germany

Investigational Site, Karl-Marx-Straße 46

Berlin, Germany

Investigational Site, Martin-Luther-Straße 134

Berlin, Germany

Investigational Site, Mohrenstraße 6

Berlin, Germany

Investigational Site, Myslowitzer Straße 49

Berlin, Germany

...and 95 more locations